诺瓦瓦克斯医药（NVAX）今日盘中大跌5.08%，引发市场关注。股价下跌主要源于该公司新冠疫苗审批进程的不确定性。
据《华尔街日报》报道，美国食品和药物管理局（FDA）已经错过了对诺瓦瓦克斯COVID-19疫苗作出关键决定的最后期限。FDA领导层目前正搁置这一决定，并表示诺瓦瓦克斯的申请需要更多数据。这一消息导致市场对该公司新冠疫苗短期内获批的预期降低。
分析人士认为，FDA的延迟决定可能会对诺瓦瓦克斯的市场前景产生负面影响。由于新冠疫苗市场竞争激烈，审批延迟可能导致公司错失重要的市场机会。投资者正密切关注公司后续的应对措施以及FDA的进一步决定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.